Beneficial for:

• Efficacy against HPV infection: Numerous clinical trials have demonstrated the high efficacy of HPV vaccines in preventing infection with HPV types included in the vaccine. The vaccines have been shown to provide protection against the most common high-risk HPV types, such as HPV-16 and HPV-18, which are responsible for the majority of cervical cancers, as well as other HPV types that cause genital warts and some other HPV-related cancers.
• Prevention of precancerous lesions and cervical cancer: HPV vaccination has been shown to significantly reduce the incidence of high-grade cervical intraepithelial neoplasia (CIN), which are precancerous lesions of the cervix. 
• Reduction in genital warts: HPV vaccines have been found to be highly effective in preventing genital warts, which are caused by certain HPV types. 
• Long-term protection: Follow-up studies of vaccinated individuals have shown sustained protection against HPV infection and associated diseases for up to 10 years after vaccination. The vaccines have demonstrated a durable immune response, providing long-term protection against HPV-related diseases.
• Herd immunity and population impact: HPV vaccination has shown significant population-level benefits due to herd immunity. By reducing the prevalence of HPV infection in the population, vaccination indirectly protects unvaccinated individuals by reducing the transmission of the virus. This has led to a decline in HPV infection rates, precancerous lesions, and cervical cancer incidence in vaccinated populations.
• Safety profile: Extensive safety data from clinical trials and post-marketing surveillance have shown that HPV vaccines are generally safe and well-tolerated. Common side effects are usually mild and temporary, such as pain at the injection site or transient fever. Serious adverse events are extremely rare.